M4 receptor Inhibitors
1 drugsAbout M4 receptor
The M4 receptor is a muscarinic acetylcholine receptor and GPCR involved in physiological processes via cholinergic neurotransmission. It has garnered attention as a drug target, particularly in respiratory diseases.
While no genetic evidence directly links the M4 receptor to specific diseases, its role in cholinergic neurotransmission makes it a potential therapeutic target.
One FDA-approved drug, tiotropium bromide, targets the M4 receptor for respiratory indications. This drug is a small molecule developed by Lupin, approved in 2023.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top M4 receptor Drugs
Lupin is the only company with an approved drug targeting the M4 receptor.
The market is highly concentrated, suggesting high barriers to entry or limited commercial interest.
M4 receptor Drug Modality Landscape
Modalities
Routes of Administration
M4 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting the M4 receptor.
M4 receptor Clinical Trials 123 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 12 | 0 | 2 | 100% |
| Phase 2 | 24 | 21 | 3 | 0 | 88% |
| Phase 3 | 44 | 42 | 2 | 0 | 95% |
| Phase 4 | 41 | 38 | 3 | 0 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M4 receptor Drug Approval Timeline (2012 - 2023)
The first and only drug targeting M4 was approved in 2023.
The recent approval suggests renewed interest, but the single approval indicates potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 50 clinical trials targeting M4 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities